Skip to content

FitMi Plus Home Therapy for Stroke Patients

FitMi Plus: Smart Functional Modules for Practicing Activities of Daily Living After Stroke

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03935425
Enrollment
50
Registered
2019-05-02
Start date
2021-11-29
Completion date
2022-12-31
Last updated
2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Stroke

Brief summary

The investigators will investigate the efficacy of a newly developed functional exercise device (FitMi Plus) for people in the chronic stage after a stroke compared to the FitMi Basic (i.e. without functional exercises). FitMi Plus combines objects commonly used during activities of daily living with sensors that can track and record the patient's direction and degree of movement as they perform specific functional tasks described on a computer.

Interventions

DEVICEFitMi Plus

A set of common objects that couple with a wireless sensor platform to allow the performance of functional exercises to be measured by a motivating software platform.

DEVICEFitMi Basic

A wireless sensor platform that allows movement subcomponents and point-to-point exercises to be measured by a motivating software platform.

Sponsors

University of California, Irvine
CollaboratorOTHER
Rancho Research Institute, Inc.
CollaboratorOTHER
Flint Rehabilitation Devices, LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Experienced 1 or more strokes \>6 months prior to enrollment * Upper Extremity Fugl-Meyer Score \>=15 and \<=55 out of 66 * Absence of moderate to severe upper extremity pain (\<= 4 out of 10 on the visual-analog pain scale) * Ability to understand the instructions to operate FitMi products

Exclusion criteria

* Lack of concurrent severe medical problems * Lack of visual deficits * Lack of severe neglect or apraxia * No concurrent enrollment in another therapy study

Design outcomes

Primary

MeasureTime frameDescription
Change in Motor Activity LogBaseline and One-Month Post-Treatment, at seven weeksA self-reported measure of the quality of movement and amount of use of the impaired upper extremity across a set of activities of daily living. Minimum value = 0, maximum value = 5, higher scores = better outcome

Secondary

MeasureTime frameDescription
Change in Upper Extremity Fugl-MeyerBaseline and One-Month Post-Treatment, at seven weeksA standardized assessment of arm impairment based on scores of 0-2 on 33 different tasks. Minimum value = 0, maximum value = 66, higher scores = better outcome

Countries

United States

Participant flow

Participants by arm

ArmCount
FitMi Plus
Participants will perform targeted movement exercises by interacting with the FitMi Plus Functional modules at least 50% of the time they spend exercising. Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks. FitMi Plus: A set of common objects that couple with a wireless sensor platform to allow the performance of functional exercises to be measured by a motivating software platform.
25
FitMi Basic
Participants will perform targeted movement exercises by interacting with the FitMi Basic pucks, as described and monitored on a computer. Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks. FitMi Basic: A wireless sensor platform that allows movement subcomponents and point-to-point exercises to be measured by a motivating software platform.
25
Total50

Baseline characteristics

CharacteristicFitMi BasicTotalFitMi Plus
Age, Continuous54.0 years
STANDARD_DEVIATION 13
55.2 years
STANDARD_DEVIATION 13.9
56.4 years
STANDARD_DEVIATION 14.7
Ethnicity (NIH/OMB)
Hispanic or Latino
12 Participants25 Participants13 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
13 Participants21 Participants8 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants4 Participants4 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
3 Participants9 Participants6 Participants
Race (NIH/OMB)
Black or African American
1 Participants5 Participants4 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
12 Participants20 Participants8 Participants
Race (NIH/OMB)
White
9 Participants16 Participants7 Participants
Sex: Female, Male
Female
6 Participants14 Participants8 Participants
Sex: Female, Male
Male
19 Participants36 Participants17 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 250 / 25
other
Total, other adverse events
0 / 250 / 25
serious
Total, serious adverse events
0 / 250 / 25

Outcome results

Primary

Change in Motor Activity Log

A self-reported measure of the quality of movement and amount of use of the impaired upper extremity across a set of activities of daily living. Minimum value = 0, maximum value = 5, higher scores = better outcome

Time frame: Baseline and One-Month Post-Treatment, at seven weeks

ArmMeasureGroupValue (MEAN)Dispersion
FitMi PlusChange in Motor Activity LogAmount of Use0.60 score on a scaleStandard Deviation 0.53
FitMi PlusChange in Motor Activity LogQuality of Movement0.64 score on a scaleStandard Deviation 0.48
FitMi BasicChange in Motor Activity LogAmount of Use0.40 score on a scaleStandard Deviation 0.39
FitMi BasicChange in Motor Activity LogQuality of Movement0.44 score on a scaleStandard Deviation 0.35
p-value: 0.11t-test, 2 sided
Secondary

Change in Upper Extremity Fugl-Meyer

A standardized assessment of arm impairment based on scores of 0-2 on 33 different tasks. Minimum value = 0, maximum value = 66, higher scores = better outcome

Time frame: Baseline and One-Month Post-Treatment, at seven weeks

ArmMeasureValue (MEAN)Dispersion
FitMi PlusChange in Upper Extremity Fugl-Meyer2.0 score on a scaleStandard Deviation 3.3
FitMi BasicChange in Upper Extremity Fugl-Meyer1.0 score on a scaleStandard Deviation 2.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026